Search results
Results From The WOW.Com Content Network
Increased risk of cancer. [32] Lumiracoxib (Prexige) 2007–2008 Worldwide Liver damage Lysergic acid diethylamide (LSD) 1950s–1960s Marketed as a psychiatric drug; withdrawn after it became widely used recreationally. Now illegal in most of the world. Mebanazine: 1975 UK Hepatotoxicity, drug intereaction. [3] Methandrostenolone: 1982
This is a list of chemotherapeutic agents, also known as cytotoxic agents or cytostatic drugs, that are known to be of use in chemotherapy for cancer.This list is organized by type of agent, although the subsections are not necessarily definitive and are subject to revision.
A MEK inhibitor is a chemical or drug that inhibits the mitogen-activated protein kinase enzymes MEK1 and/or MEK2. They can be used to affect the MAPK/ERK pathway which is often overactive in some cancers. (See MAPK/ERK pathway#Clinical significance.)
The American Cancer Society has found no evidence that antineoplastons have any beneficial effects in cancer, and it has recommended that people do not spend money on antineoplaston treatments. [136] Apitherapy – the use of products derived from bees, such as honey and bee venom, as a therapy. Apitherapy has been promoted for its anti-cancer ...
Moxibustion in Michael Bernhard Valentini's Museum Museorum (Frankfurt am Main, 1714) Moxibustion (Chinese: 灸; pinyin: jiǔ) is a traditional Chinese medicine therapy which consists of burning dried mugwort on particular points on the body.
[77] [78] In 2020 a man in Canada who was receiving antiandrogen drug treatment for colon cancer murdered his doctor over the belief that they were chemically castrating him due to his race. Chemical castration involves the administration of antiandrogen drugs, such as cyproterone acetate , flutamide , or gonadotropin-releasing hormone agonists .
Health Canada (HC; French: Santé Canada, SC) [NB 1] is the department of the Government of Canada responsible for national health policy.The department itself is also responsible for numerous federal health-related agencies, including the Canadian Food Inspection Agency (CFIA) and the Public Health Agency of Canada (PHAC), among others.
The EUND pathway was developed to allow a mechanism for authorization of these drugs based on non-clinical and limited clinical information. A manufacturer of a new drug may file an extraordinary use new drug submission for the new drug if, under paragraph C.08.002.01(1): [2] (a) the new drug is intended for